OTCMarketbulls.com Reports NASDAQ Movers For January 22, 2010

PRLog (Press Release) - Jan 22, 2010 -
As www.otcmarketbulls.com gains worldwide recognition we are rapidly becoming the MOST influential investing community available and we feel it is our obligation to show our appreciation by offering an all cash $20,000 giveaway!

OTCMarketBulls is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring value to shareholders. Some of our past picks had soared as much as 4600%. To view some of our profiled stocks, please visit our website at http://www.otcmarketbulls.com/OTCMBlandingpage.php.

Visit Us On Twitter and Facebook: http://twitter.com/otcmarketbulls http://www.facebook.com/otcmarketbulls

CNXT LATEST NEWS

Conexant Exceeds Guidance for First Quarter of Fiscal 2010 Company Delivers Core Operating Margin of 22 Percent of Revenues, Core EPS of $0.17 NEWPORT BEACH, Calif.--(1/21/10)--Conexant Systems, Inc. (NASDAQ: CNXT) today announced that financial results for the first quarter of fiscal 2010 exceeded guidance provided at the beginning of the quarter. In addition, the company said that it delivered core gross margins of 61 percent of revenues, core operating margins of approximately 22 percent of revenues, and core earnings of $0.17 per share. Both margin rates were the highest in company history.

First Fiscal Quarter Financial Results

Conexant presents financial results based on Generally Accepted Accounting Principles (GAAP) as well as select non-GAAP financial measures intended to reflect its core results of operations. The company believes these core financial measures provide investors with additional insight into its underlying operating results. Core financial measures exclude certain non-cash and other non-core items as fully described in the GAAP to non-GAAP reconciliation in the accompanying financial data.

For the first quarter of fiscal 2010, Conexant's revenues were $61.8 million. Core gross margins were 61 percent of revenues. Core operating expenses were $24.2 million, core operating income was $13.5 million, and core net income was $10.0 million, or $0.17 per share.

ANDS LATEST NEWS

Anadys Pharmaceuticals Provides Progress Update on Phase II Study of ANA598 in Hepatitis C Patients ANA598 dosing completed in the 200 mg bid cohort Enrollment completed in the 400 mg bid cohort SAN DIEGO, Jan. 22 -- Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS) today announced that ANA598 dosing has been completed in the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients. Anadys expects to receive 12-week safety and antiviral response data for the 200 mg bid cohort in the first quarter of 2010. Anadys also announced that all patients have commenced dosing in the second dose cohort, 400 mg bid. With patient enrollment in this cohort completed, Anadys has accelerated the expected timing to receive 4-week safety and antiviral response at 400 mg bid to the end of the first quarter of 2010 and continues to expect 12-week safety and antiviral response data in the second quarter of 2010.

"We are very pleased with the rapid progress of this study and appreciate the commitment of everyone involved in the trial," said Steve Worland, Ph.D., President and Chief Executive Officer of Anadys. "With continuing positive data, we hope to see ANA598 established as the leading non-nucleoside in HCV, suitable for combination with current standard of care as well as with other direct antivirals currently in development."

ISRG LATEST NEWS

SUNNYVALE, Calif., Jan. 21, 2010 -- Intuitive Surgical, Inc. (Nasdaq:ISRG), the industry leader in surgical robotics, today reported fourth quarter of 2009 revenue of $323.0 million, up 40% compared with $231.5 million for the fourth quarter of 2008. Fourth quarter of 2009 revenue growth was driven by continued robotic procedure adoption and higher da Vinci Surgical System sales.

Fourth quarter of 2009 instruments and accessories revenue increased 39% to $113.3 million from $81.6 million in the fourth quarter of 2008. The growth in instruments and accessories revenue was primarily driven by growth in da Vinci surgical procedures of approximately 44%. Fourth quarter of 2009 systems revenue was $162.0 million, an increase of 42%, compared to $113.8 million during the fourth quarter of 2008. Fourth quarter of 2009 service revenue increased 32% to $47.8 million from $36.2 million during the fourth quarter of 2008, reflecting growth in the installed base of da Vinci Surgical Systems.

SOMX LATEST NEWS

Somaxon Provides Update on New Drug Application for Silenor for the Treatment of Insomnia Resubmission has been filed, with 2 month review cycle

SAN DIEGO--(1/21/10)--Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for Silenor (doxepin) for the treatment of insomnia.

OTCMarketbulls.com is an online financial destination where money managers, analysts, and individual investors can converge to discover new and exciting investment news, opportunities, and ideas. OTCMarketBulls.com is focused on finding emerging growth companies that do not necessarily have widespread analyst coverage on Wall Street. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTCMarketBulls.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

For full disclaimer/disclosure: http://www.otcmarketbulls.com/disclaimer.php